Breast Cancer Clinical Trial
Official title:
Robotic Nipple-Sparing Mastectomy And Immediate Robotic Breast Reconstruction Vs Conventional Open Technique: A Prospective Randomized Trial Evaluating Patients Satisfaction
| Verified date | June 2023 |
| Source | European Institute of Oncology |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
This trial is designed to compare robotic nipple-sparing mastectomy and immediate robotic breast reconstruction with conventional open technique. It is a prospective randomized trial evaluating patients satisfaction
| Status | Active, not recruiting |
| Enrollment | 82 |
| Est. completion date | December 10, 2023 |
| Est. primary completion date | December 10, 2023 |
| Accepts healthy volunteers | No |
| Gender | Female |
| Age group | 18 Years and older |
| Eligibility | Inclusion Criteria: - Invasive breast cancer, Ductal Carcinoma In Situ, Breast Related Cancer Antigens mutation carriers. - Any age - Candidates to nipple-sparing mastectomy and immediate breast reconstruction - Negative preoperative assessment of nipple-areola complex - Absence of skin involvement - Low probability to have positivity of nipple-areola complex tissue intra-operative frozen section - Breast volume = Bra IV; from cup A to D - No hard smoking (hard smoking defined as >20 cigarettes/day) - Low and intermediate risk for anesthesia (ASA Scale) - Written informed consent must be signed and dated by the patient and the investigator prior to inclusion - Patients must be accessible for follow-up Exclusion criteria: - Previous thoracic radiation therapy for any reason - Inflammatory Breast Cancer - Skin involvement - Pre-operative diagnosis (radiological or cytological) of nipple-areola complex disease - Pregnancy - Patients with psychiatric, addictive, or any disorder, which compromises ability to give informed consent for participation in this study - Uncompensated Diabetes Mellitus - Hard smokers (hard smoking defined as >20 cigarettes/day) - High risk for anesthesia |
| Country | Name | City | State |
|---|---|---|---|
| Italy | European Institute of Oncology | Milan |
| Lead Sponsor | Collaborator |
|---|---|
| European Institute of Oncology |
Italy,
Toesca A, Peradze N, Galimberti V, Manconi A, Intra M, Gentilini O, Sances D, Negri D, Veronesi G, Rietjens M, Zurrida S, Luini A, Veronesi U, Veronesi P. Robotic Nipple-sparing Mastectomy and Immediate Breast Reconstruction With Implant: First Report of — View Citation
Toesca A, Peradze N, Manconi A, Galimberti V, Intra M, Colleoni M, Bonanni B, Curigliano G, Rietjens M, Viale G, Sacchini V, Veronesi P. Robotic nipple-sparing mastectomy for the treatment of breast cancer: Feasibility and safety study. Breast. 2017 Feb;3 — View Citation
Toesca A, Peradze N, Manconi A, Nevola Teixeira LF. Reply to the letter to the editor "Robotic-assisted Nipple Sparing Mastectomy: A feasibility study on cadaveric models" by Sarfati B. et al. J Plast Reconstr Aesthet Surg. 2017 Apr;70(4):558-560. doi: 10 — View Citation
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Patient satisfaction | The BREAST-Q survey is used to detect differences in patient satisfaction among the groups | 1 year | |
| Secondary | Average length of stay of patients | Reduction of the average length of stay of patients of the two different surgical techniques. | 1 month | |
| Secondary | Post operative complications | Compare post operative complications (pain, skin or nipple-areola injury or necrosis or infection, hematoma, seroma) | 1 month | |
| Secondary | Cumulative incidence of local recurrence | Cumulative incidence of local recurrence | 5 years | |
| Secondary | Cumulative incidence of axillary recurrences | Cumulative incidence of axillary recurrences | 5 years | |
| Secondary | Cumulative incidence of distant recurrences | Cumulative incidence of distant recurrences | 5 years | |
| Secondary | Disease free survival | Disease free survival | 5 years | |
| Secondary | Overall survival | Overall survival | 5 years |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
| Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
| Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
| Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
| Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
| Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
| Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
| Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
| Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
| Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
| Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
| Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
| Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
| Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
| Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
| Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
| Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
| Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A |